Abstract: 【Abstract】Children born small for gestational age infant (SGA) have a 5- to 7-fold higher risk of developing short stature in adulthood compared with those of normal birth weight. Additionally, their risk of developing metabolic diseases also increases. In recent years, recombinant human growth hormone (rhGH) has been used to increase the height of SGA children aged 2 to 4 years who exhibit insufficient catch-up growth. After 3 to 7 years of treatment, adult height can be increased by 6.9-12.6 cm. Overall, the safety profile of rhGH is favorable. Common adverse reactions include local pain and redness at the injection site, which mostly resolve spontaneously. A small proportion of children may experience transient hyperglycemia, hypothyroidism, and other metabolic abnormalities.
王萍萍 张彦 杨素红. 小于胎龄儿生长激素治疗进展[J]. 发育医学电子杂志, 2025, 13(5): 385-390.
Wang Pingping, Zhang Yan, Yang Suhong. Progress in growth hormone therapy for small for gestational age infants. Journal of Developmental Medicine(Electronic Version), 2025, 13(5): 385-390.
2025, Vol. 13 
